12 Week, Double-Blind, Fixed Dose Comparison of 20 and 40
mg daily of Study Drug and Placebo in Patients Suffering from
Posttraumatic Stress Disorder (PTSD).
Study of the Safety and Efficacy of Study Drug in the Treatment
Manic or Mixed Episodes in Subjects with Bipolar I Disorder.
Extension Study of the Safety and Tolerability of Study Drug
in Subjects with
Bipolar Disorderwho Completed Protocol Study Drug.
Drug for the Treatment of Tardive Dyskinesia in Schizophrenic
Combination of Study Drug and Study Drug in Treatment Resistant
Placebo-Controlled Study of Study Drug and Paroxetine in Patients
with Panic Disorder
Safety Study of Study Drug Patients with Anxiety Disorders
Randomized, Double-Blind, Placebo- and Risperidone-Controlled,
Multicenter Study to
Evaluate the Efficacy and Safety of Two Nonoverlapping Dose
Ranges of Study Drug given BID for 42 days to Schizophrenic
Patients with Acute or Subacute Exacerbation, Followed by
a Risperidone-Controlled, Long-Term Treatment Phase with Study
Drug given QD.
Comparative Efficacy of Study Drug, Risperidone, and Haloperidol
for Cognition in
Multicenter, Randomized, Double-Blind, Placebo Controlled
Study of Three Fixed Doses of Study Drug in the Treatment
of Institutionalized Patients with Psychosis Associated with
Dementia of the Alzheimer's Type.
Double-Blind, Placebo-Controlled, 3-Arm Fixed Dose Study of
Study Drug Continuous
Treatment for Premenstrual Dysphoric Disorder.